DE/EN
  • Deutsch
  • English
  • About us
    • His­tory
    • Who we are
    • Man­age­ment
    • Found­a­tion
    • Super­vis­ory Board
    • Sci­entific Advis­ory Board
    • Sci­entific Advisors
  • Back­ground
  • Research
    • Pro­jects
    • Tech­no­lo­gies
    • Pub­lic­a­tions
  • Ser­vices
    • Gen­ome Editing
    • Human iPS cells
    • Meas­ure­ments to accom­pany (pre-)clinical studies
    • Reg­u­lat­ory services
  • Co-Oper­­a­­tions
  • News
  • Jobs
  • Con­tact
REPROGRAM - REFINE - REGENERATE REPROGRAM - REFINE - REGENERATE REPROGRAM - REFINE - REGENERATE REPROGRAM - REFINE - REGENERATE
  • About us
    • His­tory
    • Who we are
    • Man­age­ment
    • Found­a­tion
    • Super­vis­ory Board
    • Sci­entific Advis­ory Board
    • Sci­entific Advisors
  • Back­ground
  • Research
    • Pro­jects
    • Tech­no­lo­gies
    • Pub­lic­a­tions
  • Ser­vices
    • Gen­ome Editing
    • Human iPS cells
    • Meas­ure­ments to accom­pany (pre-)clinical studies
    • Reg­u­lat­ory services
  • Co-Oper­­a­­tions
  • News
  • Jobs
  • Con­tact

Neurodegenerative diseases

Home » Publications » Neurodegenerative diseases
Asym­metry of Fib­ril­lar Plaque Bur­den in Amyl­oid Mouse Models
0
By
In Neurodegenerative diseases, Publications
Posted 29. August 2020

Asym­metry of Fib­ril­lar Plaque Bur­den in Amyl­oid Mouse Models

Investigating the symmetry of fibrillar plaques on AD mouse models confirms an asymmetric pattern, similar to Alzheimer’s disease patients, which translated into regional microglia activation.

READ MORE
Anti-Trem2 anti­body treat­ment as Alzheimer therapy
0
By
In Neurodegenerative diseases, Publications
Posted 28. August 2020

Anti-Trem2 anti­body treat­ment as Alzheimer therapy

Modulating Trem2 signaling through Trem2 antagonistic antibodies can alter microglia function and cause disease-relevant changes in Alzheimer’s disease.

READ MORE
sTREM2, a poten­tial bio­marker in AD
0
By
In Neurodegenerative diseases, Publications
Posted 28. December 2019

sTREM2, a poten­tial bio­marker in AD

sTREM2 correlates with microglia activation, and higher CSF sTREM2 levels can be linked to reduced cognitive decline and slower rates of Plaque accumulation in AD patients.


READ MORE
  • +49 89 356 475 400
  • info@isarbioscience.de
NAVIGATION
  • About us
  • Back­ground
  • Research
  • Ser­vices
  • Co-Oper­­a­­tions
  • News
  • Jobs
  • Con­tact
© 2022 ISAR Bioscience. All rights reserved.
  • Cookie Set­tings
  • Pri­vacy Policy
  • Legal Inform­a­tion
  • DeutschDeutsch